new product – ReportWire

Roche's Inavolisib Breast Cancer Drug Shows Promise in Late-Stage Study

[ad_1]

By Mauro Orru

Roche Holding said its investigational treatment, inavolisib, showed promise in a late-stage study to treat patients with breast cancer.

The Swiss pharmaceutical company said Tuesday that the phase 3 study met its primary endpoint of progression-free survival, showing that inavolisib, in combination with palbociclib and fulvestrant, delivered a statistically significant and clinically meaningful improvement compared to palbociclib and fulvestrant alone.

While Roche acknowledged that overall survival data were immature at this stage, it said it had observed a clear positive trend. The inavolisib combination was well tolerated.

The group said inavolisib is an investigational, oral targeted treatment with potential to provide durable disease control.

Write to Mauro Orru at mauro.orru@wsj.com

[ad_2]

Source link

December 4, 2023

Novartis Says Kidney Drug Phase 3 Trial Reaches Positive Interim Result

[ad_1]

By Adria Calatayud

Novartis said an interim analysis from a phase 3 trial to evaluate its investigational iptacopan drug in patients with kidney disease nephropathy achieved positive results, meeting its primary goal.

The Swiss pharmaceutical company said Monday that an analysis of study data at nine months showed a clinically meaningful and statistically significant reduction in protein in urine. The company said this demonstrated superiority of iptacopan relative to placebo in reducing protein in urine.

The safety profile of the drug was consistent with previously reported data, Novartis said.

Novartis said it plans to review the trial’s interim results with the U.S. Food and Drug Administration to enable a potential regulatory submission for accelerated approval.

The study will now continue to assess the iptacopan’s ability to slow disease progression over two years, the company said. Results from the primary goal at the end of the study are expected in 2025.

Write to Adria Calatayud at adria.calatayud@dowjones.com

[ad_2]

Source link

October 1, 2023

Roche Lung Cancer Drug Shows Promise in Phase 3 Trial

[ad_1]

By David Sachs

Roche said Friday that its Alecensa drug demonstrated the ability to reduce recurrence of lung cancer for patients in the early stage of the disease.

The Swiss pharmaceutical company said the results, from a Phase 3 study of 257 people which compared the treatment with platinum-based chemotherapy, met its primary goal of disease-free survival in people with early-stage non-small cell lung cancer. About half of people with this type of lung cancer experience a recurrence of the disease after surgery, Roche said.

Roche said that it found no unexpected safety issues and will submit the data to global health authorities.

Write to David Sachs at david.sachs@wsj.com

[ad_2]

Source link

August 31, 2023

BioVie Shares jump Premarket on Parkinson’s, Alzheimer’s Studies >BIVI

[ad_1]

By Colin Kellaher

Shares of BioVie Inc. rose sharply in premarket trading Tuesday after the clinical-stage biopharmaceutical company reported positive results from a pair of Phase 2 studies assessing the potential of its NE3107 drug candidate in Parkinson’s disease and Alzheimer’s disease.

The Carson City, Nev., company said the study of NE3107 in Parkinson’s met both main objectives, with patients treated with a combination of the drug and levodopa seeing meaningful improvements in their motor score and an absence of adverse interactions of NE3107 with levodopa.

BioVie said that based on the study findings, it will proceed with planning the Phase 3 program for discussion with the U.S. Food and Drug Administration.

Meanwhile, BioVie said patients treated with NE3107 in the Alzheimer’s study experienced improved cognition and biomarker levels, with no drug-related adverse events observed.

BioVie shares, which closed Monday at $5.21, were recently up 15% to $5.98 in premarket trading.

Write to Colin Kellaher at colin.kellaher@wsj.com

[ad_2]

Source link

December 6, 2022

GSK Says Dreamm-3 Phase 3 Study For Blenrep Didn’t Meet Primary Endpoint

[ad_1]

By Michael Susin

GSK PLC said Monday that its Dreamm-3 Phase 3 study in patients with relapsed or refractory multiple myeloma didn’t meet its primary endpoint of progression-free survival.

The pharmaceutical giant said that the study compared its monotherapy Blenrep versus pomalidomide in combination with low dose dexamethasone and observed median progression-free survival was longer for Blenrep.

“These trials are designed to demonstrate the benefit of Blenrep in combination treatment with novel therapies and standard-of-care treatments in earlier lines of therapy and dosing optimization to maintain efficacy while reducing corneal events,” it added.

The company said additional trials will continue and further data from the studies are anticipated in the first half of 2023.

Write to Michael Susin at michael.susin@wsj.com

[ad_2]

Source link

November 7, 2022

Moderna Stock Takes Off on Cancer Vaccine News

[ad_1]

Moderna

stock shot up after

Merck

said it is exercising an option to work on a personalized cancer vaccine with the Covid-19 vaccine maker.

Merck (ticker: MRK) will pay

Moderna

(MRNA) $250 million for the joint development and future commercialization of the vaccine, which is currently in Phase 2 clinical trials. The two companies had announced a “strategic collaboration” in June 2016.

[ad_2]

Source link

October 12, 2022

Smart City Projects Are Not Only Big City Projects: RealTerm Energy Launches MyTown, a New Smart City Solution Designed Specifically for Small and Medium-Sized Municipalities

[ad_1]

Press Release
–

updated: Apr 16, 2019

ANNAPOLIS, Md., April 16, 2019 (Newswire.com)
–
RealTerm Energy launches MyTown, a new smart city app and asset management platform, made specifically for small and medium-sized municipalities, that is set to revolutionize the way local governments and citizens communicate. MyTown, which is now available as a free download for both Apple and Android devices, improves citizens’ connections with their communities while staff and elected officials become better informed and more responsive to citizen feedback.

MyTown provides citizens with access to a wide range of public notices and events, customizable tabs such as garbage and recycling calendars, along with school and bus alerts, updates regarding road closures, parking, water-use restrictions, sidewalk construction, hospital wait-times and a great deal more. MyTown can provide citizens with over 30 different types of information sources. The app also enables users to report problems, like a pothole, a streetlight outage, a parking concern and even facilitates the anonymous disclosure of sensitive information to law enforcement or school administration officials via the HotLine tool. The app has already proven to be of great value to over 30 cities of various sizes and to 3.6 million citizens across North America.

MyTown’s Smart Maps tile unlocks the potential of real-time location intelligence and creates the foundation for next-generation geo-spatial systems and IoT connectivity all on a platform that is built to military grade security protocols. Smart Maps tracks and displays information for the municipality in real-time by linking multiple IoT devices on to one platform enabling optimized asset management for assets such as buses, garbage trucks, smart streetlights and snow removal equipment. It also enables the tracking of important sensors and equipment such as air quality, water quality, noise, video and numerous others. Smart Maps is powered by Luciad, part of Hexagon Geospatial, utilized by organizations such as NATO, SAP Hana and Airbus Defense and Space.

“We are very excited to be launching MyTown. Our goal is to provide municipalities, regardless of their size, with access to advanced software and technologies at an extremely affordable price. Now, more than ever, MyTown is needed to improve communication between citizens and city staff and is required to support rapid and informed decision-making at city halls everywhere. We are certain that this application and asset management platform will quickly improve communities with minimal effort,” explains Sean Neely, CEO of RealTerm Energy.

To learn more about MyTown, visit: www.mytownsmartcity.com or contact us directly at mytown@realtermenergy.com

About RealTerm Energy

RealTerm Energy supports municipalities in becoming Smart City-ready with MyTown, its Smart City app and municipal asset management platform. The organization is also redefining the municipal streetlighting market with smart lighting solutions and services that deliver unmatched energy and maintenance savings. RealTerm Energy creates and fosters long-term partnerships with forward-thinking private, public and government market leaders to deliver innovative and cost-effective lighting solutions that make a real difference. For more information visit www.realtermenergy.com and follow us on Twitter @RealTermEnergy and LinkedIn.

CONTACT

Rebecca Handfield

Marketing Manager, RealTerm Energy

rhandfield@realtermenergy.com

1-866-422-5200

Source: RealTerm Energy

[ad_2]

Source link

April 16, 2019

Chicago Comb Company Receives 2 Design Patents for Metal Combs

[ad_1]

The award-winning Chicago Comb Company has been granted one of the most distinguished awards for their products. They have been issued two design patents for their unique combs by the United States Patent Office.

Press Release
–

updated: May 9, 2017

Chicago, IL, May 9, 2017 (Newswire.com)
–
The award-winning Chicago Comb Company has been granted one of the most distinguished awards for their products. They have been issued two design patents for their unique combs by the United States Patent Office — one for each of their two flagship products, the design of their Number 1 and Number 2 combs.

“We couldn’t be happier,” says co-founder John Litwinski. “We’ve spent many hours in crafting not only our unique designs, but we put a lot of attention on creating a high-quality product. We live in a time when it is very easy to copy products. Now that we have these patents, the worry of competitors copying us with inferior products has been taken out of the equation.”

“We’ve spent many hours in crafting not only our unique designs, but we put a lot of attention on creating a high-quality product. We live in a time when it is very easy to copy products. Now that we have these patents, the worry of competitors copying us with inferior products has been taken out of the equation.”

John Litwinski, co-founder

The Chicago Comb Company was founded by two childhood friends, John and Tedd, in 2010. Since starting their business, they have seen a steady growth in sales year after year, and the combs are now featured in retailers in 23 countries across the world. Their passion for quality and their keen sense of detail has brought to life a unique everyday item that will stand the test of time.

The patented No. 1 and No. 2 combs were the first combs ever to be laser cut out of steel in the US. The combs are then hand finished in their workshop in Chicago. All the steel that makes up the combs is sourced in the US as well as their packaging.

“One of our core values is local production. From the laser cutting of the combs to the machine and hand finishing, all are done right here in Chicago. Not a lot of companies can say that — it’s something we are very proud of,” says co-founder Tedd Strom.

The Chicago Comb Company has expanded over the years, and now offers five different design models of combs, each with a matte, mirror or black finish. In addition, they offer their patented designs in pure American Titanium – the only comb in the world to do so. Each of their designs is accompanied by a leather sheath using top-quality leather from Chicago’s world-famous Horween tannery.

They offer custom engraving on their website (www.chicagocomb.com), perfect for any special occasion or event, as well as limited supply of combs featuring the designs of acclaimed artists engraved on the combs.

Source: Chicago Comb Company

[ad_2]

Source link

May 9, 2017

Tag: new product